Genomic medicine, the next major biotech era, is primarily pre-commercial though a few medicines have been approved. The list of FDA-approved cellular and gene therapy products did increase in July when the second Kite Pharma (GILD) cell therapy - Tecartus - was approved for relapsed/refractory mantel cell lymphoma or r/r MCL.
This article continues my series on genomic medicines. Updates, including a tracking group of companies pursuing genomic therapies, can prove useful to anyone analyzing the sector. The companies in the tracking group are: Abeona (ABEO), Allogene (ALLO), Atara